Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: KEGG:D05364 (
PTH
)
6,818
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The present studies were designed to examine in vivo effects of glucocorticoid on
PTH
-or
calcitonin
(CT)-stimulated adenosine 3',5'-monophosphate (cAMP) release from the isolated perfused bone of rat and to test whether the duration of glucocorticoid administration influenced such effects. We assessed the ability of acute (24 hour) or chronic (2 week) dexamethasone administration to modulate the cAMP response to 5 micrograms human
PTH
-(1-34) or 1 micrograms eel CT. Acute treatment with dexamethasone (1 mg/100 g body wt) increased the cAMP response to
PTH
, but decreased the response to CT. This enhanced effect on
PTH
-stimulated cAMP release was not apparent in the presence of phosphodiesterase inhibitor 3-isobutyl-1-methyl-xanthine (IBMX, ImM). In contrast, chronic dexamethasone treatment (0.2 mg daily for 2 weeks) led to a decrease in both
PTH
- and CT-stimulated cAMP release. Such impaired response of the dexamethasone-treated bones to
PTH
was also found in rats that underwent parathyroidectomy 24 hours before sacrifice. These data indicate that 1) the duration of glucocorticoid administration may influence the effect of
PTH
on bone and 2) glucocorticoid may decrease cAMP-mediated CT function, regardless of the duration of treatment.
...
PMID:Altered parathyroid hormone- or calcitonin-stimulated adenosine 3', 5'-monophosphate release by isolated perfused bone from glucocorticoid-treated rats. 242 9
The hormone-sensitive adenylate cyclase system of a cloned bone cell line (UMR-106) derived from a rat osteosarcoma was compared in preparations from cells of early passages (less than 50) and cells maintained in continuous culture for over two years (late passages). Late passage cells showed greater
calcitonin
(CT)-stimulated adenylate cyclase activity than did early passages, whereas stimulation by
PTH
and the beta-adrenergic agonist isoproterenol decreased in late passages. Hormone concentrations giving half-maximal stimulation were the same in early and late passages. Stimulation by agents (GTP and fluoride) which act at the stimulatory guanine nucleotide regulatory component (Ns) of adenylate cyclase was equivalent in early and late passages. Forskolin stimulation, which assessed catalytic component (and possibly Ns) activity, was reduced in late passages. These results are consistent with acquisition by cultured UMR-106 cells of CT receptors linked to adenylate cyclase and loss of
PTH
and beta-adrenergic receptors. Alteration of catalytic component (and/or Ns) function may also occur after long-term culture. Since late passage cells appear dedifferentiated by chromosomal analysis and since cAMP may regulate differentiation, altered hormone-sensitive adenylate cyclase may be a marker for and a potential modulator of differentiation occurring in UMR-106 cells over long periods.
...
PMID:Alterations in hormone-sensitive adenylate cyclase of cloned rat osteosarcoma cells during long-term culture. 245 11
Insulin has potent effects on osteoblast function both in vivo and in vitro. In various insulin-sensitive tissues, stimulation of glucose transport and metabolism are hallmarks of insulin action, and have been postulated to play a role in insulin regulation of cellular function. However, insulin effects on glucose metabolism in osteoblast-like cells have not been demonstrated. Therefore we examined the in vitro effects of insulin on hexose uptake in an osteoblast-enriched rat bone explant preparation. Uniform 5-mm-diameter punch sections were obtained from the cartilage-free frontal portions of the calvaria of 3-day-old rats, and the periosteum was removed. The resulting sections contained a highly enriched population of osteoblast-like cells as determined by histologic criteria, elimination of
calcitonin
-stimulatable cAMP generation, and enhancement of
PTH
-stimulatable cAMP generation per microgram of DNA. Sections were incubated for 24 hr at 37 degrees C in BGJb medium and then transferred to modified glucose-free Krebs-Ringer bicarbonate buffer for 2-deoxy-D-glucose (2-DG) uptake studies. 3H-2-DG uptake was linear with time over 60 min, temperature sensitive, and inhibited by 5 mM phloridzin. Kinetic analysis of 2-DG uptake at 25 degrees C demonstrated a saturable transport mechanism with a Km of 2.2 mM, similar to that observed for 2-DG transport in other tissues. Studies of competitive inhibition by other sugars demonstrated a transport specificity for 2-DG that was comparable to that previously observed in fat and muscle cells.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Glucose transport in osteoblast-enriched bone explants: characterization and insulin regulation. 246 40
In order to investigate the pathophysiology of anticonvulsant-induced osteopenia, circulating levels of bone gamma-carboxyglutamic acid-containing protein (Bone Gla Protein: BGP) and urinary excretion of BGP were measured in 16 children on chronic anticonvulsant therapy and in 12 control children. Using microdensitometry analysis, osteopenia was found in 25% of the anticonvulsant therapy group, but it was not observed in the control group. Serum BGP and A1-P levels were significantly increased in the anticonvulsant group compared with the control group (P less than 0.05 and P less than 0.01, respectively), and a positive correlation was found between serum BGP and A1-P levels (P less than 0.05). Urinary excretion of BGP and hydroxyproline showed an increase in the anticonvulsant group, but it was not statistically significant. On the other hand, there was no significant difference between the two groups in serum levels of vitamin D metabolites,
PTH
,
calcitonin
, Ca, or P or in urinary excretion of Ca or P. It is suggested, therefore, that the increased BGP level in children receiving anticonvulsant therapy is a reflection of high bone turnover due to anticonvulsant drug complications.
...
PMID:Increased circulating levels of gamma-carboxyglutamic acid-containing protein and decreased bone mass in children on anticonvulsant therapy. 249 94
To examine the effects of serum calcium concentrations on
PTH
biosynthesis, rats were made hyper- (serum total calcium, approximately 3.5 mM) or hypocalcemic (approximately 1.25 mM) and steady-state levels of
PTH
mRNA in parathyroid cells were measured by the primer extension method using a 32P-labeled synthetic oligomer.
PTH
mRNA levels increased about twofold in the rats made slightly hypocalcemic by infusion of calcium-free solution and decreased slightly in those made hypercalcemic by CaCl2 infusion (120-150 mumol/h) compared with the levels present in nonfasting control rats. Infusion of
calcitonin
(0.5 U/h) or EGTA (90 mumol/h) with calcium-free solution increased
PTH
mRNA levels further (two- to sevenfold) above the levels present in animals infused with calcium-free solution alone. These changes in
PTH
mRNA levels were observed after 48- but not 24-h infusion, and there was an inverse correlation between
PTH
mRNA levels and serum calcium concentrations. The results suggest that changes in serum calcium concentrations in the near physiological range regulate the biosynthesis of
PTH
by affecting steady-state levels of
PTH
mRNA when hypercalcemia or hypocalcemia continues for a relatively long period.
...
PMID:Hypocalcemia increases and hypercalcemia decreases the steady-state level of parathyroid hormone messenger RNA in the rat. 249 84
Serum levels of ionized calcium, 25-hydroxyvitamin D (25OHD), and 1,25-dihydroxyvitamin D[1,25-(OH)2D], intact immunoreactive
PTH
and
calcitonin
were measured in the laboratory rabbit to evaluate the role of these calciotropic hormones in calcium homeostasis in this species. We confirm the finding of previous researchers that the resting serum ionized and total calcium concentrations are elevated in rabbits compared to those in other species (ionized calcium, 1.70 +/- 0.13 mmol/liter; total calcium, 3.23 +/- 0.25 mmol/liter). The serum calcium concentrations in animals maintained on a breeding farm or in the laboratory did not differ significantly despite nearly 3-fold higher levels of vitamin D in the feed at the farm, which were associated with 3- to 4-fold higher concentrations of 25OHD and 1,25-(OH)2D. Baseline intact
PTH
levels for the farm and laboratory populations also did not differ significantly and averaged 69.4 +/- 43.6 human pgeq/ml (laboratory animals, 52.1 +/- 28.4; breeding farm animals, 86.0 +/- 49.5 human pgeq/ml). Infusions of calcium gluconate or EDTA for 15 min into anesthetized animals in the laboratory induced dramatic reciprocal changes in the measured circulating levels of
PTH
. Calcium gluconate infusions (190-300 nmol/g BW) produced 50-85% increases in serum ionized calcium, which were accompanied by 74-91% decreases in
PTH
levels (from 68.8 +/- 29.2 at time zero to 10.1 +/- 3.1 human pgeq/ml at 15 min) as well as 7-fold increases in
calcitonin
levels. EDTA infusions (14-120 nmol/g BW) reduced serum ionized calcium by 9-49%, while
PTH
levels increased by 68-560% (from 61.4 +/- 32.3 at time zero to a maximum of 138 +/- 48.6 human pgeq/ml at 3 min). During the EDTA infusion, the
PTH
response was variable after 3 min despite further decreases in ionized Ca2+, indicating either exhaustion of
PTH
reserves or regulation of the secretory response by some parameter other than ionized calcium concentration per se. Thus, the rabbit appears to defend its serum ionized calcium concentration against hypo- and hypercalcemia by rapid changes in
PTH
secretion and
calcitonin
. Unlike other mammalian species, however, the changes in
PTH
occur at relatively high levels of calcium, suggesting that the parathyroid gland of the rabbit is reset to respond to changes in ionized Ca2+ within the physiological range in that species. The relative insensitivity of the rabbit parathyroid to extracellular calcium is analogous to that observed in primary hyperparathyroidism and may be a useful model to study the control of normal and abnormal
PTH
secretion.
...
PMID:Regulation of calciotropic hormones in vivo in the New Zealand white rabbit. 250 95
The calcium signal plays an important role in the control of the secretory process of some adenohypophyseal hormones which responds to the administration of calciotropic substances by a marked change. In the submitted work the effect of
calcitonin
and 1,25(OH)2-vitamin D3 (1,25(OH)2D3) on FSH, LH and testosterone secretion was investigated. A single dose of 50 U synthetic salmon
calcitonin
did not influence the FSH, LH and testosterone secretion at rest nor stimulated secretion. 1,25(OH)2D3 administered for four days in amounts of 3 micrograms/day did not affect the LH and testosterone secretion but increased slightly the secretory response of FSH to LHRH, significantly during the 80th minute following administration of the secretagogue (P less than 0.01). The indication of bi-phasic FSH secretion was eliminated by 1,25(OH)2D3. The significant decline of
PTH
levels following administration of 1,25(OH)2D3 is evidence of a biologically effective level of 1,25(OH)2D3 attained by the administered dose of hormone. As compared with the marked effect of
calcitonin
and 1,25(OH)2D3 on thyrotropic hormone secretion, it may be concluded that the gonadotropic system is considerably less sensitive to a change of calcium homeostasis induced by
calcitonin
or 1,25(OH)2D3. Nevertheless a slight increase of the FSH secretion and a change of the dynamics of its secretion suggest a modulating role of 1,25(OH)2D3 in the control of FSH secretion.
...
PMID:Effect of calcitonin and 1,25(OH)2-vitamin D3 on the FSH, LH and testosterone secretion at rest and LHRH stimulated secretion. 251 39
To investigate the effects of the LH-RH agonist Buserelin [D-Ser (But)6 des-Gly10-LHRH ethylamide] on endometriosis, 64 patients were treated with 900 micrograms/d Buserelin intranasally over 6 months after histological verification of the disease. As shown by the follow-up operation at the end of treatment, 73% of cases showed regression of implants, whereas adhesions seemed to be unaffected. The uncorrected pregnancy rate of the 45 patients with a history of infertility was 40%, while the overall recurrence rate--confirmed by histological examination--was 9.4%. The endocrine parameters demonstrated a highly significant suppression of estradiol (E2) and a sharp decline of progesterone (Prog), indicating anovulatory cycles. Follicle-stimulating hormone (FSH) was unchanged, while luteinizing hormone (LH) and prolactin (Prl) decreased significantly. The androgenic parameters testosterone (T), dehydroepiandrosterone sulfate (DHEA-S), and sex-hormone-binding globulin (SHBG) revealed no relevant changes. Influence on bone metabolism could not be detected by measuring
calcitonin
and parathyroid hormone fragments (
PTH
-C and
PTH
-MM). Negative metabolic effects were absent in terms of hematology, clotting system, liver enzymes, renal parameters and lipid metabolism. Remarkable was a significant increase of high-density-lipoprotein cholesterol (HDL). Subjective complaints were mostly attributed to the therapy-induced hypoestrogenism. We consider Buserelin to be an effective drug in the treatment of endometriosis, with a low incidence of relevant side effects.
...
PMID:LH-RH agonist (buserelin): treatment of endometriosis. Clinical, laparoscopic, endocrine and metabolic evaluation. 251 11
Chronic low doses of hPTH-(1-34) stimulate bone growth in rats in vivo. The objective of these studies was to determine if the anabolic effect of hPTH-(1-34) on rat bone in vivo is dependent on an initial stimulation of resorption by blocking resorption with either salmon
calcitonin
(CT) or dichloromethylene diphosphonate (Cl2MDP). Male Sprague-Dawley rats, 70-100 g, were treated with daily subcutaneous (SC) injections of vehicle (V) or hPTH-(1-34), 8 micrograms per 100 g (
PTH
), for 12 days. In experiment 1, rats were given CT for 3 (CT3) or 12 (CT12) days, either alone or in combination with hPTH-(1-34) (CT3-
PTH
and CT12-
PTH
) or vehicle for 12 days. In experiment 2, rats were pretreated for 4 days with Cl2MDP or its vehicle before starting the daily
PTH
or vehicle injections. Rats were then killed. Sera, femora, tibiae, and kidneys were removed for chemical and histomorphometric analyses.
PTH
,
PTH
-CT3, and
PTH
-CT12 rats showed significant increases in total bone calcium (18-23%), dry weight (DW, 13-25%), and bone-forming surfaces compared with their respective controls. Eroded (resorption) surfaces were comparable between the groups. Although weight gain and serum calcium were normal in rats treated for 3 days with CT, rats treated for 12 days with CT gained 14% less weight than controls and were hypophosphatemic, with reduced serum calcium and urea nitrogen. Total bone mass increased both in Cl2MDP rats (Ca 21%, DW 2%), where resorption was presumably blocked, and in
PTH
rats (Ca 31%, DW 19%). The increase in bone mass was greater in
PTH
-Cl2MDP rats (Ca 48%, DW 29%) than in rats treated with Cl2MDP alone, suggesting that although Cl2MDP blocked resorption, the anabolic response to
PTH
was not altered. As neither short-term treatment with CT nor Cl2MDP blocked the anabolic response of bone to hPTH-(1-34), this response does not appear to depend on the early stimulation of resorption.
...
PMID:Resorption is not essential for the stimulation of bone growth by hPTH-(1-34) in rats in vivo. 252 59
Bovine parathyroid hormone (bPTH 1-34) caused a time- and dose-dependent enhanced formation of the two prostanoids PGE2 and 6-keto-PGF1 alpha in cultured neonatal mouse calvarial bones, with threshold for action at 0.1 nmol/l. The PGE2 response to
PTH
was completely blocked by indomethacin, but insensitive to
calcitonin
. By contrast, indomethacin was without effect on 45Ca release induced by
PTH
. The
PTH
analogues (Nle 8, 18, Tyr 34)-bPTH (3-34) amide and (Tyr 34)-bPTH (7-34) amide, which are putative
PTH
antagonists, did not affect basal production of PGE2, nor did the analogues affect bPTH 1-34 induced PGE2 formation. The data show that
PTH
stimulates prostanoid formation in mouse bone cells and that this response is not directly linked to
PTH
-induced bone resorption.
...
PMID:Parathyroid hormone stimulates prostanoid formation in mouse calvarial bones. 253 89
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>